{"brief_title": "The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT", "brief_summary": "To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.", "detailed_description": "Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks. PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Lamivudine", "Zidovudine", "Zalcitabine"], "criteria": "Inclusion Criteria Patients must have: - HIV positivity. - CD4 count 100-300 cells/mm3. - Prior AZT therapy for 24 or more weeks and currently on AZT. Exclusion Criteria Patients with the following prior conditions are excluded: - History of intolerance to AZT. - History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: - Any prior antiretroviral therapy other than AZT. Required: - Concomitant AZT therapy. Required: - At least 24 weeks of prior AZT.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Zidovudine", "mesh_term": ["HIV Infections", "Zidovudine", "Zalcitabine", "Lamivudine"], "id": "NCT00002436"}